Down 63% in 2024, what’s going on with the Avacta (AVCT) share price?

2024 has been a difficult year for many companies in the biotechnology sector, with the AVCT share price down heavily. But is there potential here?

| More on:
Illustration of flames over a black background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceutical developer Avacta Group (LSE:AVCT), also known as AVCT, is one of the UK’s leading diagnostics and cancer therapies, but has seen its share price plummet by a staggering 63% in 2024. This dramatic decline has left many investors wondering what has triggered this downward spiral in the AVCT share price. So is there more pain ahead, or is there a potential opportunity here?

What went wrong?

Many of us will know the company from the development of Covid-19 lateral flow tests. However, since then, the share price has been incredibly volatile. Since the peak in 2020, when shares hit £2.74 and the market cap was £340m, the value of the company has sunk to £154m.

Several factors seem to be at play here. Many are commonplace in the biotech sector, but I still have a few major concerns.

Avacta, like many other pre-revenue companies in the biotech sector, has yet to turn a profit. The company’s earnings per share are forecasted to decline in the coming years, which has dampened investor confidence.

The firm boasts impressive revenue growth of 34% over the past five years. However, it seems this growth might be falling short of lofty investor expectations. With enormous rallies in previous years this disappointment has naturally led to a sell-off, driving the share price down.

Business has also been hampered by difficulties in obtaining regulatory approvals for new diagnostics and therapies. Delays in securing the rights for a new antigen testing kit in May 2023 further eroded investor confidence.

The biggest red flag for me is the dilution of shares in the company, with 31% more shares outstanding than a year ago. In February 2024, the business raised funds through a share sale at a significantly discounted price. To me, this sounds like an action the company wouldn’t do unless it really had to, sending very worrying signals.

Is there hope?

While the recent performance has been undeniably bleak, there are some positive signs for Avacta. The company finally received the ISO 13485 certification last year, allowing its tests to be used in Europe. This could lead to increased sales and potentially a turnaround in fortunes.

When compared to others in the sector, the price-to-sales (P/S) ratio of 6.6 times is well below the average of 10.2 times. There is clearly a future in the technology being used here. So if a company can grow sustainably, and build a market share large enough, it could well be a winner in the long term.


The share price decline is a complex issue, requiring a decent amount of technical knowledge of the sector. The short-term outlook might seem uncertain, but the company’s progress in regulatory approvals and its potential for future growth could represent a good opportunity for patient investors. However, I think there are less complex and more lucrative investments out there, so I’ll be staying well clear for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Gordon Best has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

Down 75%! Will the Saga share price ever be loved again?

The last few years have been incredibly difficult for those watching the Saga share price. But what does the future…

Read more »

Investing Articles

What kind of return could I expect by investing £100 monthly in a Stocks and Shares ISA?

Using a Stocks and Shares ISA to avoid capital gains tax could grow a £100 monthly investment into a second…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Can strong operational momentum keep the Informa share price rising?

FTSE 100 company Informa has been performing well, but this may be just the beginning of a multi-year trend for…

Read more »

Market Movers

What’s going on with the Britvic share price?

Jon Smith flags up why Britvic's share price is surging on Friday, but believes that the company is in a…

Read more »

Cheerful young businesspeople with laptop working in office
Dividend Shares

2 super-cheap passive income shares I’m eyeing up right now

Jon Smith discusses two of his favourite passive income shares in the banking and property sectors, both featuring yields above…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Up 37.5% in just 12 months, I think this is one of the FTSE 100’s best investments

Our author says this FTSE 100 company is likely to keep on capitalising on the AI and data boom. But…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

This UK share just spiked 15% on bid news. Can we bag a quick profit?

UK share prices are having a good 2024, so far, and this one's already up 39%. Two takeover bids in…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

I’m ‘blowing a raspberry’ at Raspberry Pi shares. Here’s why

Some early investors have made great profits from Raspberry Pi shares. But our writer's questioning whether the 'easy money' has…

Read more »